Recent findings on drug hypersensitivity in children

Drug hypersensitivity reactions (DHR) in children have a significant impact on clinical practice and public health. Both under-diagnosis (due to under-reporting) and over-diagnosis (due to the overuse of the term “allergy”) are potential issues. The aim of this narrative review is to describe the most recent findings of DHR in children/adolescents and gaps regarding epidemiology, antibiotic allergy, antiepileptic hypersensitivity, vaccine allergy, and severe cutaneous adverse reactions (SCAR) in this age group.

Introduction

Drug hypersensitivity reactions (DHR) in children/adolescents have a significant impact on clinical practice and public health (1, 2). Both under-diagnosis (due to under-reporting) and over-diagnosis (due to the overuse of the term “allergy”) are potential issues. Antibiotic allergy is often reported and not properly diagnosed in pediatric age groups (1, 2). Maculopapular exanthems (MPE) and even urticaria during treatment with antibiotics, especially beta-lactams (BL), are often labeled as drug allergy, but the vast majority are caused by infection or the interaction between medication and viruses (1, 2). Furthermore, other adverse drug reactions (ADR), such as headache or gastrointestinal intolerance, are mistaken for real allergic reactions (1, 2).

DHR are unpredictable reactions that can be reproduced by administering a suspected drug at doses normally tolerated by other individuals (3–5). They may be mediated by immunological (allergic types) or non-immune (non-allergic types) mechanisms (4, 5). DHR can also be classified according to the time they occur after drug administration (4, 5). Immediate reactions may occur within 1–6 h after the first dose of the drug and are generally IgE-mediated (4–6). Non-immediate reactions occur after 1 h, but more frequently after days of drug administration, and are generally mediated by T cells (4–6).

The aim of this article is to describe the most recent findings of DHR in children/adolescents and gaps regarding epidemiology, antibiotic allergy, antiepileptic hypersensitivity, vaccine allergy, and severe cutaneous adverse reactions (SCAR) in this age group.

Methods

To write this narrative review, the authors searched for information on PubMed and selected publications from January 1990 to July 2023, using the following keywords: “drug hypersensitivity”; “antibiotic allergy”; “antiepileptic hypersensitivity”; “vaccine”; “severe cutaneous adverse reactions”; “childhood”; “pediatric”; and “adolescence”. The inclusion criteria were any type of publication (systematic reviews, randomized clinical trials, observational studies, case series, position statements, and selected reviews) on drug hypersensitivity related to children and adolescents, written in English.

The selection of topics considered the drugs most involved in DHR in children, the most severe reactions, and some issues of special interest in the pediatric age group, such as allergy to vaccines and antiepileptic drugs. For articles, the selection was made according to relevance, date of publication, and inclusion of pediatric patients. Therefore, in general, more recent articles and some reviews focused on pediatric age published by recognized researchers in drug allergy were included. Being a mini review, a limitation of this article is that it could not cover all topics related to pediatric drug allergy.

Epidemiology of drug allergy in children

There are fewer epidemiological studies on drug allergy in children compared to adults. Most of them reveal that many children with suspected drug allergies are not, in fact, allergic (7, 8). Unfortunately, they often carry this false allergy label into adulthood (7, 8). It is important to highlight that the diagnosis of DHR should be based not only on clinical history, but also on skin tests (ST), validated in vitro tests, and drug provocation tests (DPT) (6, 8).

Recently, Capanoglu et al. evaluated 5,553 children with suspected drug allergies (9). Parents were asked “Has your child ever developed any allergies after using drugs?”, and 7% (389) answered that their child had drug allergies. Pediatric allergists suspected that 21.1% (n = 82/389) had drug allergies. After diagnostic tests, drug allergy was confirmed in 4.2% (n = 3/72). Therefore, the frequency of suspected drug allergy was 1.47% (n = 82/5553), and the prevalence of confirmed drug allergy was 0.05% (n = 3/5,553) (9).

Another study investigating DHR in children was conducted in Serbia (10). They evaluated 504 patients, with a mean age of 7.5 years. There were 375 children with a history suggestive of single-drug hypersensitivity and 129 with multiple-drug hypersensitivity. The main drugs involved were antibiotics (83%), non-steroidal anti-inflammatory drugs (NSAIDs) (8.4%), and antipyretics (3.8%). There was skin involvement in 96.2%. DHR were confirmed in 4.4% —six patients had positive ST and 13 had a positive DPT. In the proven DHR group, the main culprits were antibiotics (72.7%), followed by NSAIDs (8.3%). Urticaria was the most common skin manifestation (78.2%), followed by exanthema (10.5%) and angioedema (5.3%). The presence of extracutaneous manifestations was significantly associated with a positive allergy test (p = 0.022, OR 4.62, 95% CI 1.05–15.76%) (10).

Antibiotic allergy and its impact on child health

The most frequent cause of DHR mediated by immune mechanisms in children is antibiotics, especially BL (11). Around 10% of parents report an allergy to BL in their children (12). After proper evaluation by an allergist, nearly 95% of these children will be able to tolerate the antibiotic (8, 11, 12). In this age group, infections are more common (mainly viral infections) and can mimic drug allergies or act as cofactors.

The “penicillin allergy” label is associated with many adverse effects in individual and global health. The patient labeled as “allergic to penicillin” uses more broad-spectrum antibiotics, such as fluoroquinolones, vancomycin, and clindamycin, increasing the prevalence of infections by bacteria such as Clostridium difficile, methicillin-resistant Staphylococcus aureus, and vancomycin-resistant Enterococcus (13–15). In addition, studies have shown that these patients are at greater risk of postoperative complications, longer hospital stays, greater cost of treatment, and higher rate of treatment failure (13–15).

Taylor et al. investigated the epidemiology and factors associated with penicillin allergy labels in two large US pediatric primary care networks (16). They conducted a retrospective, longitudinal birth cohort study in 90 pediatric primary care clinics with 334,465 children born between January 2010 and June 2020. They found that children were labeled early in life (mean age 1.3 years), and nearly half were labeled after receiving 1 or 0 penicillin prescriptions. These findings are alarming and question the validity of penicillin allergy labels (16).

Another study demonstrated the impact of an antibiotic allergy label in childhood. Lucas et al. evaluated 1,672 pediatric patients from Perth, Australia, and found antibiotic allergy labels in 5.3% of patients, most of them BL allergy labels (85%) (17). The incidence of antibiotic allergy labels increased with age (p < .001). Patients with antibiotic allergy labels received more macrolide, quinolones, lincosamide, and metronidazole antibiotics than patients without an antibiotic allergy label (17). Furthermore, children with any antibiotic or BL allergy label had longer hospital stays (odds ratio, 1.62; 95% CI, 1.05–2.50), with a mean length of hospital stay of 3.8 days for those without a label and 5.2 days for those with a BL allergy label (17).

Appropriate assessment of antibiotic allergy is an essential part of antibiotic stewardship program efforts. Removing false labels from a patient with suspected drug allergies may reduce unnecessary exclusions. Thus, there are several publications aiming to optimize the investigation of allergy to BL (18–20). Recently, an EAACI task force published a review on BL allergy in children (21). In this article, the authors stated that DPT is almost universally advocated in non-immediate mild MPE, with sufficient evidence that ST is not mandatory in this situation (21). However, the index reaction history must be reliable, showing low risk for the patient. The ideal protocol for DPT remains to be defined. For mild immediate BL reactions, further studies are needed to confirm the safety of performing a direct DPT in children (21).

Finally, in 2023, a systematic review investigated the safety of performing direct DPT with BL without ST to guide the decision for re-exposure in children with mild BL reactions (22). They found a low prevalence of BL reactions by direct DPT (5.23%) and a very low frequency of severe reactions from direct DPT (0.036%), supporting direct DPT as a safe and effective delabeling tool in children with suspected mild BL reactions (22).

Antiepileptic hypersensitivity reactions

Antiepileptic drugs (AED) are often prescribed in childhood and are one of the most common causes of DHR in this age group (23). These reactions may present with benign MPE, but severe cutaneous adverse reactions (SCAR) are sometimes observed, such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS) (23). Acute generalized exanthematous pustulosis (AGEP) is also a SCAR, rarely caused by AED (23).

AED are classified as aromatic or non-aromatic depending on the presence of at least one aromatic ring (23). Aromatic AED (phenobarbital, phenytoin, carbamazepine, oxcarbazepine, lamotrigine, felbamate, zonisamide, and primidone) are responsible for the most serious reactions (23). In a Turkish study that evaluated 58 pediatric patients with SCAR, antibiotics were the most common culprit medication (51.7%) and AED were the second most common (31%) (24). Another analysis of two multicenter case-control studies showed that anti-infective sulfonamides and AED, especially phenobarbital, carbamazepine, and lamotrigine, were the drugs most associated with the risk of SJS/TEN in children (25). Levetiracetam is a new non-aromatic AED with a better tolerability profile. However, there are also some reports of severe reactions to this drug (23).

There are several factors involved in the pathogenesis of these DHR. Most of them are non-immediate type IV reactions, explained by the hapten/prohapten, p-i concept, and altered peptide repertoire hypotheses (23). However, other theories are being proposed to help understand the mechanisms related to these AED hypersensitivity reactions (AED-HR). The “danger hypothesis” postulates that some signals derived from viral infections or drug metabolism may act as cofactors to promote immune modulation (23). Furthermore, genetic polymorphisms and HLA alleles have been described as risk factors for certain SCAR in specific populations (23). The associations between HLA alleles/genetic polymorphisms and AED-HR observed in studies with children are presented in Table 1 (26–30).

Table 1

Table 1. Associations between HLA alleles/genetic polymorphisms and AED-HR among children.

Management of patients with a history of AED hypersensitivity is difficult, as many of these patients require ongoing treatment of seizures. Avoidance of all aromatic AED is generally recommended in patients who react to one of these medications, and non-aromatic AED may be an option (23).

Vaccine allergy

Vaccines and their components can cause hypersensitivity reactions. However, true hypersensitivity to vaccines is rare and signs and symptoms appearing after vaccination may be coincidental (31, 32). Vaccination is a public health action, and it is necessary to evaluate children through a complete allergy work-up. Vaccine hesitancy is one of the biggest threats to global health, emphasizing the importance of allergists and pediatricians in promoting vaccine safety (31, 32).

True vaccine allergy is found in <10% of children investigated in allergy units after a potential vaccine hypersensitivity reaction (31). A vaccination reaction should be referred to as an adverse event following immunization (AEFI) until it can be categorized (31).

All vaccines can cause immediate and non-immediate immunological reactions. Fortunately, most of these reactions are mild. Anaphylaxis and SCAR are extremely rare (32, 33). When investigating patients with AEFI, it is important to consider that individual vaccine components, including active immunizing antigens, conjugating agents, preservatives, stabilizers, antimicrobial agents, adjuvants, and culture media, may be possible allergic triggers (31, 32). Specific guidelines including testing with the different vaccine components as well as the vaccine itself have been published (33–35).

Fear of an allergic reaction can cause vaccine hesitancy. This has recently been observed with COVID-19 vaccines, which have been associated with cutaneous and systemic reactions. However, the incidence of anaphylaxis after COVID-19 vaccines is comparable to that of other vaccines (36). Another rare AEFI found in children and adolescents, especially in male adolescents after receiving mRNA vaccines, is myocarditis/pericarditis (37). These patients require close monitoring, but most of them improve quickly after treatment (37). Considering the risk/benefit ratio, an international guideline published in 2022 suggested vaccination against COVID-19 for children/adolescents aged between 3 and 17 years, monitoring possible side effects after vaccination (38).

One of the most common situations involving vaccine allergies is the evaluation of children with suspected food allergy (e.g., egg, milk, gelatin) (34). Regarding egg-allergic children, several studies have already demonstrated the safety of the measles-mumps-rubella (MMR) vaccine for these patients (34). This is also true for most injected inactivated influenza vaccines (34). The management of egg-allergic patients who need a yellow fever vaccine (YFV) is more complex. A Brazilian study investigated the safety of YFV in confirmed egg-allergic patients and concluded that the administration of YFV using a specific protocol was safe in these patients (39). The IDT was useful in predicting a higher risk of vaccine reaction (39).

In children with systemic and/or cutaneous mastocytosis, vaccines may trigger hypersensitivity reactions by mast cell mediator release. Some experts recommend premedication after a reaction in these patients; however, there is no consensus regarding this issue (40). Avoiding the simultaneous administration of multiple vaccines is another measure that may be useful (40).

Severe cutaneous adverse reactions (SCAR) in children

Severe cutaneous adverse drug reactions are rare conditions that can be fatal. They include DRESS, SJS/TEN, and AGEP.

A Turkish study mentioned above investigated pediatric patients with SCAR and found a median age of 8.2 years (50% were male) (24). There was SJS/TEN in 60.4% (n = 35), DRESS in 27.6% (n = 16), and AGEP in 12% (n = 7) of patients (24). Drugs were the cause of reactions in 93.1% of children, mainly antibiotics and AED. Only one patient (with TEN) died (24). Another study conducted in France analyzed 49 pediatric cases of DRESS (41). The median age was 8 years (44.9% were male). The most frequent culprit drugs were antibiotics (65%) and AED (27.5%) (41).

Drug reaction with eosinophilia and systemic symptoms (DRESS)

DRESS is a severe and potentially fatal drug-induced, cell-mediated reaction (41.42). AED (mainly aromatic) and antibiotics are the most commonly involved medications (41, 42). The incidence of DRESS due to anticonvulsants is 1:1,000–1:10,000 in the general population (43) and 0.4:1,000 (44) in hospital settings. Its incidence is lower in children than in adults (42), and the mortality rate is approximately 10%, with a lower percentage in children than in adults (42, 45).

The exact pathogenic mechanism of DRESS is unknown, but some genetic studies have found an association between HLA haplotypes and susceptibility to DRESS (26, 30). Furthermore, there appears to be a role for viral reactivation during DRESS, especially Human Herpes virus (HHV-6), as well as Epstein Barr virus (EBV), cytomegalovirus (CMV), and HHV-7 (46).

The time latency of DRESS symptoms ranges from 2 to 6 weeks after initiation of treatment. In children, the average age of occurrence of DRESS syndrome is 9 years of age (42, 45). The main clinical manifestations of DRESS are fever (usually high); facial edema; MPE (but other cutaneous reactions may occur, such as urticarial, pustular, bullous, lichenoid, exfoliative, and eczematous rashes); lymphadenopathy; hematological abnormalities, like leukocytosis with eosinophilia and/or atypical lymphocytosis; and organ involvement (hepatitis, nephritis, pneumonitis) (41, 42).

The diagnosis of DRESS is based on different criteria. The most frequently used are the European Registry of Serious Cutaneous Adverse Drug Reactions (RegiSCAR) or the Japanese Serious Cutaneous Adverse Drug Reactions (SCAR-J) group (47, 48). They include clinical signs and symptoms (fever, rash), hematological abnormalities, and organ involvement (47, 48). The Japanese group also included HHV-6 reactivation in their criteria (48).

Treatment begins with the withdrawal of all medications suspected of causing DRESS (41, 42). Mild cases are treated with topical corticosteroids and emollients. Moderate and severe cases are usually treated with systemic corticosteroids (41, 42). There are case reports of good response to other medications, including cyclosporine, azathioprine, infliximab, and mycophenolate, in patients with more severe disease (42). Intravenous immunoglobulin (IVIG) may be useful in some patients, but its benefit is still controversial (42).

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)

SJS and TEN are rare severe cutaneous adverse drug reactions mediated by cytotoxic T cells (mainly CD8+). There is extensive epidermal necrosis and detachment, with mucocutaneous complications (49, 50). SJS and TEN differ only along a spectrum of severity based on percentage of body surface area detached (<10% in SJS; 10%–30% in an overlap SJS/TEN; and >30% in TEN) (49). Hsu et al. reported an incidence rate of 5.3 and 0.4 cases per million children for SJS and TEN, respectively, with an equal incidence between male and female children (51). In children, as in adults, drugs are the most frequent triggers of SJS/TEN (49, 50). Common culprit medications are sulfa antibiotics, AED, and NSAIDs (49).

The early manifestations of SJS/TEN include fever, malaise, and anorexia (50). It progresses with cutaneous lesions and bullae. SJS/TEN can mimic other illnesses, such as erythema multiforme major (EMM), staphylococcal scalded skin syndrome (SSSS), or autoimmune blistering diseases (49, 50). Table 2 shows some differences in clinical characteristics and main causes between SJS/TEN and other cutaneous diseases (49–56).

Table 2

Table 2. Differential diagnosis of SJS/TEN and other cutaneous disorders in children.

In SJS/TEN, the denuded skin areas may be associated with pain, fluid and protein loss, electrolyte imbalances, and bleeding (49). They also predispose to bacterial superinfection, most commonly by Staphylococcus aureus and Pseudomonas aeruginosa (49). Ophthalmic disorders with sequelae are frequent, affecting up to 30% of children and adults (49).

The treatment is based on early detection and removal of the offending agents. Patients should be admitted to an intensive care unit or burn center as quickly as possible (49, 50). Supportive care is comprised of wound and eye care; fluid and electrolyte management; nutritional support; and prompt treatment of infections (49, 50). Systemic treatment includes corticosteroids, cyclosporine, and etanercept, with some promising outcomes (50). IVIG in high doses (2 g/kg) is another therapeutic option (49, 50).

Acute generalized exanthematous pustulosis (AGEP)

AGEP is a rare, severe cutaneous adverse reaction. It is most commonly caused by drugs but can also be triggered by infections, especially in children (52). It is characterized by fever, pinhead-sized nonfollicular sterile pustules on erythematous skin lesions mostly in the face and intertriginous areas, leukocytosis, and rare organ involvement (52). Among all the SCAR, it is considered less severe with a lower rate of mortality (52).

Conclusions

Drug allergy in children is an important issue, with an impact on individual healthcare, limiting treatment options and causing more adverse effects, and on public healthcare, increasing bacterial resistance, costs, and length of hospital stay. Many of these young patients carry allergy medication labels into adulthood. Therefore, the removal of false allergy labels in this age group should be encouraged as part of public health policies. Strategies to optimize BL allergy investigation, such as direct DPT without ST, are being implemented. Studies investigating the most frequent DHR, optimized diagnostic methods, and more appropriate management in pediatrics should be encouraged.

Author contributions

MF: Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review & editing. FK: Writing – review & editing. JB: Writing – review & editing. MC: Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Doña I, Caubet JC, Brockow K, Doyle M, Moreno E, Terreehorst I, et al. An EAACI task force report: recognising the potential of the primary care physician in the diagnosis and management of drug hypersensitivity. Clin Transl Allergy. (2018) 8:16. doi: 10.1186/s13601-018-0202-2

Crossref Full Text | Google Scholar

2. Abrams E, Netchiporouk E, Miedzybrodzki B, Ben-Shoshan M. Antibiotic allergy in children: more than just a label. Int Arch Allergy Immunol. (2019) 180(2):103–12. doi: 10.1159/000501518

PubMed Abstract | Crossref Full Text | Google Scholar

3. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the nomenclature review committee of the world allergy organization, October 2003. J Allergy Clin Immunol. (2004) 113:832–6. doi: 10.1016/j.jaci.2003.12.591

PubMed Abstract | Crossref Full Text | Google Scholar

4. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, et al. International consensus on drug allergy. Allergy. (2014) 69(4):420–37. doi: 10.1111/all.12350

PubMed Abstract | Crossref Full Text | Google Scholar

5. Demoly P, Castells M. Important questions in drug allergy and hypersensitivity: consensus papers from the 2018 AAAAI/WAO international drug allergy symposium. World Allergy Organ J. (2018) 11(1):42. doi: 10.1186/s40413-018-0224-1

PubMed Abstract | Crossref Full Text | Google Scholar

6. Romano A, Atanaskovic-Markovic M, Barbaud A, Bircher AJ, Brockow K, Caubet JC, et al. Towards a more precise diagnosis of hypersensitivity to beta-lactams—an EAACI position paper. Allergy. (2020) 75(6):1300–15. doi: 10.1111/all.14122

PubMed Abstract | Crossref Full Text | Google Scholar

7. Norton AE, Konvinse K, Phillips EJ, Broyles AD. Antibiotic allergy in pediatrics. Pediatrics. (2018) 141(5):e20172497. doi: 10.1542/peds.2017-2497

PubMed Abstract | Crossref Full Text | Google Scholar

8. Gomes ER, Brockow K, Kuyucu S, Saretta F, Mori F, Blanca-Lopez N, et al. Terreehorst I; ENDA/EAACI drug allergy interest group. Drug hypersensitivity in children: report from the pediatric task force of the EAACI drug allergy interest group. Allergy. (2016) 71(2):149–61. doi: 10.1111/all.12774

PubMed Abstract | Crossref Full Text | Google Scholar

9. Capanoglu M, Erkocoglu M, Kaya A, Dibek Misirlioglu E, Ginis T, Toyran M, et al. Confirmation of drug allergy in a general pediatrics outpatient clinic. Ann Allergy Asthma Immunol. (2022) 129(6):784–9. doi: 10.1016/j.anai.2022.09.017

PubMed Abstract | Crossref Full Text | Google Scholar

10. Milosevic K, Malinic M, Plavec D, Lekovic Z, Lekovic A, Cobeljic M, et al. Diagnosing single and multiple drug hypersensitivity in children: a tertiary care center retrospective study. Children (Basel). (2022) 9(12):1954. doi: 10.3390/children9121954

PubMed Abstract | Crossref Full Text | Google Scholar

11. Vyles D, Adams J, Chiu A, Simpson P, Nimmer M, Brousseau DC. Allergy testing in children with low-risk penicillin allergy symptoms. Pediatrics. (2017) 140(2):e20170471. doi: 10.1542/peds.2017-0471

PubMed Abstract | Crossref Full Text | Google Scholar

12. Macy E, Poon KYT. Self-reported antibiotic allergy incidence and prevalence: age and sex effects. Am J Med. (2009) 122(778):e1–7. doi: 10.1016/j.amjmed.2009.01.034

Crossref Full Text | Google Scholar

13. Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin “allergy” in hospitalized patients: a cohort study. J Allergy Clin Immunol. (2014) 133(3):790–6. doi: 10.1016/j.jaci.2013.09.021

PubMed Abstract | Crossref Full Text | Google Scholar

14. Lee CE, Zembower TR, Fotis MA, Postelnick MJ, Greenberger PA, Peterson LR, et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med. (2000) 160(18):2819–22. doi: 10.1001/archinte.160.18.2819

PubMed Abstract | Crossref Full Text | Google Scholar

15. van Dijk SM, Gardarsdottir H, Wassenberg MW, Oosterheert JJ, de Groot MC, Rockmann H. The high impact of penicillin allergy registration in hospitalized patients. J Allergy Clin Immunol Pract. (2016) 4(5):926–31. doi: 10.1016/j.jaip.2016.03.009

PubMed Abstract | Crossref Full Text | Google Scholar

16. Taylor MG, Joerger T, Li Y, Scheurer ME, Russo ME, Gerber JS, et al. Factors associated with penicillin allergy labels in electronic health records of children in 2 large US pediatric primary care networks. JAMA Netw Open. (2022) 5(3):e222117. doi: 10.1001/jamanetworkopen.2022.2117

PubMed Abstract | Crossref Full Text | Google Scholar

17. Lucas M, Arnold A, Sommerfield A, Trevenen M, Braconnier L, Schilling A, et al. Antibiotic allergy labels in children are associated with adverse clinical outcomes. J Allergy Clin Immunol Pract. (2019) 7(3):975–82. doi: 10.1016/j.jaip.2018.09.003

PubMed Abstract | Crossref Full Text | Google Scholar

18. Abrams EM, Atkinson AR, Wong T, Ben-Shoshan M. The importance of delabeling β-lactam allergy in children. J Pediatr. (2019) 204:291–7.e1. doi: 10.1016/j.jpeds.2018.09.035

PubMed Abstract | Crossref Full Text | Google Scholar

19. Felix MMR, Kuschnir FC. Direct oral provocation test is safe and effective in diagnosing beta-lactam allergy in low-risk children with mild cutaneous reactions. Front Pharmacol. (2020) 11:1223. doi: 10.3389/fphar.2020.01223

PubMed Abstract | Crossref Full Text | Google Scholar

20. Khan DA, Banerji A, Blumenthal KG, Phillips EJ, Solensky R, White AA, et al. Drug allergy: a 2022 practice parameter update. J Allergy Clin Immunol. (2022) 150(6):1333–93. doi: 10.1016/j.jaci.2022.08.028

PubMed Abstract | Crossref Full Text | Google Scholar

21. Blanca-Lopez N, Atanaskovic-Markovic M, Gomes ER, Kidon M, Kuyucu S, Mori F, et al. An EAACI task force report on allergy to beta-lactams in children: clinical entities and diagnostic procedures. Pediatr Allergy Immunol. (2021) 32(7):1426–36. doi: 10.1111/pai.13529

PubMed Abstract | Crossref Full Text | Google Scholar

22. Srisuwatchari W, Phinyo P, Chiriac AM, Saokaew S, Kulalert P. The safety of the direct drug provocation test in beta-lactam hypersensitivity in children: a systematic review and meta-analysis. J Allergy Clin Immunol Pract. (2023) 11(2):506–18. doi: 10.1016/j.jaip.2022.11.035

PubMed Abstract | Crossref Full Text | Google Scholar

23. Kuyucu S, Caubet JC. Hypersensitivity reactions to antiepileptic drugs in children: epidemiologic, pathogenetic, clinical, and diagnostic aspects. J Allergy Clin Immunol Pract. (2018) 6(6):1879–1891.e1. doi: 10.1016/j.jaip.2018.07.003

PubMed Abstract | Crossref Full Text | Google Scholar

24. Misirlioglu E D, Guvenir H, Bahceci S, Haktanir Abul M, Can D, Usta Guc BE, et al. Severe cutaneous adverse drug reactions in pediatric patients: a multicenter study. J Allergy Clin Immunol Pract. (2017) 5(3):757–63. doi: 10.1016/j.jaip.2017.02.013

PubMed Abstract | Crossref Full Text | Google Scholar

25. Levi N, Bastuji-Garin S, Mockenhaupt M, Roujeau JC, Flahault A, Kelly JP, et al. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics. (2009) 123(2):e297–304. doi: 10.1542/peds.2008-1923

PubMed Abstract | Crossref Full Text | Google Scholar

26. Amstutz U, Ross CJ, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR. Carleton BC; CPNDS consortium. HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther. (2013) 94(1):142–9. doi: 10.1038/clpt.2013.55

PubMed Abstract | Crossref Full Text | Google Scholar

27. Chong KW, Chan DW, Cheung YB, Ching LK, Hie SL, Thomas T, et al. Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore. Arch Dis Child. (2014) 99(6):581–4. doi: 10.1136/archdischild-2013-304767

PubMed Abstract | Crossref Full Text | Google Scholar

28. Manuyakorn W, Mahasirimongkol S, Likkasittipan P, Kamchaisatian W, Wattanapokayakit S, Inunchot W, et al. Association of HLA genotypes with phenobarbital hypersensitivity in children. Epilepsia. (2016) 57(10):1610–6. doi: 10.1111/epi.13509

PubMed Abstract | Crossref Full Text | Google Scholar

29. Suvichapanich S, Jittikoon J, Wichukchinda N, Kamchaisatian W, Visudtibhan A, Benjapopitak S, et al. Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children. J Hum Genet. (2015) 60(8):413–7. doi: 10.1038/jhg.2015.47

PubMed Abstract | Crossref Full Text | Google Scholar

30. Manuyakorn W, Siripool K, Kamchaisatian W, Pakakasama S, Visudtibhan A, Vilaiyuk S, et al. Phenobarbital-induced severe cutaneous adverse drug reactions are associated with CYP2C19*2 in Thai children. Pediatr Allergy Immunol. (2013) 24(3):299–303. doi: 10.1111/pai.12058

PubMed Abstract | Crossref Full Text | Google Scholar

31. Cheung A, Perrett KP. Immunisation and allergy in children and adults: a case-based approach. Aust J Gen Pract. (2020) 49(10):637–43. doi: 10.31128/AJGP-07-20-5547

PubMed Abstract | Crossref Full Text | Google Scholar

32. McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. (2018) 141(2):463–72. doi: 10.1016/j.jaci.2017.12.971

PubMed Abstract | Crossref Full Text | Google Scholar

33. Atanaskovic-Markovic M, Gomes E, Cernadas JR, du Toit G, Kidon M, Kuyucu S, et al. Diagnosis and management of drug-induced anaphylaxis in children: an EAACI position paper. Pediatr Allergy Immunol. (2019) 30(3):269–76. doi: 10.1111/pai.13034

PubMed Abstract | Crossref Full Text | Google Scholar

34. Dreskin SC, Halsey NA, Kelso JM, Wood RA, Hummell DS, Edwards KM, et al. International consensus (ICON): allergic reactions to vaccines. World Allergy Organ J. (2016) 9(1):32. doi: 10.1186/s40413-016-0120-5

PubMed Abstract | Crossref Full Text | Google Scholar

35. Caubet JC, Rudzeviciene O, Gomes E, Terreehorst I, Brockow K, Eigenmann PA. Managing a child with possible allergy to vaccine. Pediatr Allergy Immunol. (2014) 25(4):394–403. doi: 10.1111/pai.12132

PubMed Abstract | Crossref Full Text | Google Scholar

36. Maltezou HC, Hatziantoniou S, Theodoridou K, Vasileiou K, Anastassopoulou C, Tsakris A. Anaphylaxis rates following mRNA COVID-19 vaccination in children and adolescents: analysis of data reported to EudraVigilance. Vaccine. (2023) 41(14):2382–6. doi: 10.1016/j.vaccine.2023.02.067

PubMed Abstract | Crossref Full Text | Google Scholar

37. Park H, Yun KW, Kim KR, Song SH, Ahn B, Kim DR, et al. Epidemiology and clinical features of myocarditis/pericarditis before the introduction of mRNA COVID-19 vaccine in Korean children: a multicenter study. J Korean Med Sci. (2021) 36(32):e232. doi: 10.3346/jkms.2021.36.e232

PubMed Abstract | Crossref Full Text | Google Scholar

38. Liu E, Smyth RL, Li Q, Qaseem A, Florez ID, Mathew JL, et al. Guidelines for the prevention and management of children and adolescents with COVID-19. Eur J Pediatr. (2022) 181(12):4019–37. doi: 10.1007/s00431-022-04615-4

PubMed Abstract | Crossref Full Text | Google Scholar

39. Gerhardt CMB, Castro APBM, Pastorino AC, Dorna MB, Nunes-Santos CJ, Aquilante BP, et al. Safety of yellow fever vaccine administration in confirmed egg-allergic patients. Vaccine. (2020) 38(42):6539–44. doi: 10.1016/j.vaccine.2020.08.020

PubMed Abstract | Crossref Full Text | Google Scholar

40. Mori F, Crisafulli G, Bianchi A, Bottau P, Caimmi S, Franceschini F, et al. Drugs and vaccines hypersensitivity in children with mastocytosis. J Clin Med. (2022) 11(11):3153. doi: 10.3390/jcm11113153

PubMed Abstract | Crossref Full Text | Google Scholar

41. Bedouelle E, Ben Said B, Tetart F, Milpied B, Welfringer-Morin A, Maruani A, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): series of 49 French pediatric cases. J Allergy Clin Immunol Pract. (2022) 10(1):267–274.e5. doi: 10.1016/j.jaip.2021.07.025

PubMed Abstract | Crossref Full Text | Google Scholar

42. Mori F, Caffarelli C, Caimmi S, Bottau P, Liotti L, Franceschini F, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS) in children. Acta Biomed. (2019) 90(3-S):66–79. doi: 10.23750/abm.v90i3-S.8167

PubMed Abstract | Crossref Full Text | Google Scholar

43. Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Allergol Select. (2017) 4(1):96–108. doi: 10.5414/ALX01508E

Crossref Full Text | Google Scholar

44. Fiszenson-Abala F, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol. (2003) 149(5):1018–22. doi: 10.1111/j.1365-2133.2003.05584.x

PubMed Abstract | Crossref Full Text | Google Scholar

45. Newell B, Moinfar M, Mancini A, Nopper A. Retrospective analysis of 32 pediatric patients with anticonvulsant hypersensitivity syndrome (ACHSS). Pediatr Dermatol. (2009) 26:536–46. doi: 10.1111/j.1525-1470.2009.00870.x

PubMed Abstract | Crossref Full Text | Google Scholar

46. Calle AM, Aguirre N, Ardila JC, Cardona Villa R. DRESS syndrome: a literature review and treatment algorithm. World Allergy Organ J. (2023) 16(3):100673. doi: 10.1016/j.waojou.2022.100673

PubMed Abstract | Crossref Full Text | Google Scholar

47. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. RegiSCAR study group. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. (2013) 169(5):1071–80. doi: 10.1111/bjd.12501

PubMed Abstract | Crossref Full Text | Google Scholar

48. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of a DRESS syndrome has been sufficiently established on the basis of typical clinical features and viral reactivations. Br J Dermatol. (2007) 156:1083–84. doi: 10.1111/j.1365-2133.2007.07807.x

PubMed Abstract | Crossref Full Text | Google Scholar

49. Stevens-Johnson syndrome and toxic epidermal necrolysis in the pediatric population: a review. Pediatr Emerg Care. (2016) 32(7):477–8. doi: 10.1097/01.pec.0000484460.08402.93

PubMed Abstract | Crossref Full Text | Google Scholar

50. Marks ME, Botta RK, Abe R, Beachkofsky TM, Boothman I, Carleton BC, et al. Updates in SJS/TEN: collaboration, innovation, and community. Front. Med. (2023) 10:1213889. doi: 10.3389/fmed.2023.1213889

Crossref Full Text | Google Scholar

51. Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. (2017) 76(5):811–817.e4. doi: 10.1016/j.jaad.2016.12.024

PubMed Abstract | Crossref Full Text | Google Scholar

52. Lee EY, Koh MJA. Acute generalized exanthematous pustulosis in children and adolescents in Singapore: a ten-year retrospective review. Pediatr Dermatol. (2021) 38(2):424–30. doi: 10.1111/pde.14482

PubMed Abstract | Crossref Full Text | Google Scholar

53. Canavan TN, Mathes EF, Frieden I, Shinkai K. Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. J Am Acad Dermatol. (2015) 72(2):239–45. doi: 10.1016/j.jaad.2014.06.026

PubMed Abstract | Crossref Full Text | Google Scholar

54. Yun D, Stein SL. Blistering disorders in children. Pediatr Ann. (2015) 44(8):e205–12. doi: 10.3928/00904481-20150812-10

PubMed Abstract | Crossref Full Text | Google Scholar

55. Goldman RD. Erythema multiforme in children. Can Fam Physician. (2022) 68(7):507–8. doi: 10.46747/cfp.6807507

PubMed Abstract | Crossref Full Text | Google Scholar

56. Siedner-Weintraub Y, Gross I, David A, Reif S, Molho-Pessach V. Paediatric erythema multiforme: epidemiological, clinical and laboratory characteristics. Acta Derm Venereol. (2017) 97(4):489–92. doi: 10.2340/00015555-2569

PubMed Abstract | Crossref Full Text | Google Scholar